CPTx & NanoCell Therapeutics Project Awarded EU Funding for Innovative In Vivo CAR T Therapy with Immune-Silent Single-Stranded DNA
QUIET-CAR project targeting cancer and autoimmune diseases top-ranked among 120+ Eurostars Grant submissions
MUNICH, GERMANY, and SOUTH SAN FRANCISCO, CA — August 14, 2025 — CPTx, a biotechnology company developing in vivo genetic medicines built with programmable single-stranded DNA (ssDNA), announced today the QUIET-CAR collaborative project with NanoCell Therapeutics has received a Eurostars Grant from the European Union through the Horizon Europe program and Eureka Network. The focus of the QUIET-CAR project is development of targeted lipid nanoparticles carrying novel immune-silent ssDNA for in vivo CAR T therapy.
"CPTx is committed to bringing in vivo CAR T therapies to patients through our proprietary pipeline development programs and now also through the QUIET-CAR project with NanoCell,” said Hendrik Dietz, CEO of CPTx. “The QUIET-CAR project represents another innovative approach to CAR T, and we look forward to advancing it together. Being selected from so many high-quality submissions underscores the promise of the project and the strength of our technology."
Eurostars, part of the European Partnership on Innovative SMEs and supported by Horizon Europe, is a funding initiative to accelerate transnational innovation. With participation from 37 countries, the program selects only the most promising technological breakthroughs, evaluated by independent experts. The selection of the CPTx – NanoCell project from more than 120 proposals reflects QUIET-CAR’s strong scientific and clinical potential across oncology and autoimmune diseases. NanoCell Therapeutics is a privately held biotechnology company pioneering transformative in vivo cell engineering through its non-viral, DNA-based gene therapy platform, primarily targeting oncology and autoimmune diseases.
About CPTx
CPTx is redefining the future of genetic medicine through a single-stranded DNA (ssDNA) platform that enables safer, redosable, and scalable gene therapies.
CPTx’s lead proprietary development program is a new kind of in vivo CAR T-cell therapy using immune-silent single-stranded DNA (ssDNA) delivered with LNPs, enabling repeat dosing, long-lasting effects, and precise control, something not possible with viral vectors or mRNA. Through alliances with innovative companies such as the QUIET-CAR project with NanoCell Therapeutics, CPTx is also collaborating on additional approaches to the development of in vivo CAR T and genetic medicines.
CPTx’s in-house ssDNA manufacturing unit, known as gxstrands, was originally built to meet the Company’s own demanding specifications. gxstrands has since evolved into a CDMO platform of choice for pharma companies who recognize ssDNA as a critical enabler for gene and cell therapy programs. The platform provides high-quality knock-in templates for gene editing applications, including allogeneic CAR-T and stem cell editing.
Contact:
Investors:
McDavid Stilwell
mcdavid.stilwell@cptx.bio
Media:
Beth Willers
bethw@whitemattercomm.com